Abstract:Prostate cancer stands as the foremost cause of cancer-related deaths among men in the United States, with the primary treatment being androgen receptor (AR) antagonists relying on current androgen signaling knowledge. Most of this knowledge is derived from next-generation sequencing experiments, but the oversight of splice variants and highly similar sequences in multiple loci can hinder a comprehensive understanding. In an effort to unveil the complete androgen receptor transcriptional program, we employed a novel sequencing analysis protocol. Using a R1881-LNCaP model, we identified 212 upregulated and 92 downregulated genes, of which a notable one-third (68 upregulated and 39 downregulated) had not been previously associated with androgen. Among these novel transcripts, 5.6% lacked splice variants, while 16.3% exhibited one or more splice variants, including 3.8% from seven unique gene families. Recognized androgen-regulated genes, such as ORM1, STEAP4, NPPC, ORM2, and KLK3, were validated as upregulated, while GRB10, FN1, PPFIA2, and PLA2G2A were confirmed as downregulated in this in-vitro model. Utilizing chromatin immunoprecipitation-sequencing (ChIP-seq) data, we found that 13% of the genes contained at least one androgen response element within 5 kb upstream or downstream. Further validation through real-time PCR confirmed the expression levels of 90% of the selected genes (18). Ingenuity Pathway Analysis revealed two major regulators (ESRRA and ARFGEF2) in causal networks likely interacting with the novel genes. Intriguingly, 57.1% of ESRRA-involved genes contained at least one ESRRA binding site in a ChIP-seq dataset. Although ESRRA is known to activate androgen biosynthesis in castration-resistant prostate cancer, its interaction with AR and co-regulation of androgen signaling remain unknown. Ongoing studies involve the characterization of these networks in prostate cancer cell lines, examining anchorage-independent capacity, invasion, migration, proliferation, and progression. Data collection and comparison will ascertain whether the signaling is driven by mutated AR, and the role of ARv7 will be elucidated through gene lockdown experiments. Citation Format: Alex L. McDonald, Spencer Snow, Shuk-mei Ho, Yuet-kin Leung. Novel androgen related gene network in prostate cancer cell model [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular s); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl) nr 6282.

Advances in Brief PART-1 : A Novel Human Prostate-specific , Androgen-regulated Gene that Maps to Chromosome 5 q 121

Part-1: A Novel Human Prostate-Specific, Androgen-Regulated Gene That Maps To Chromosome 5q12

Abstract 476: Defining Two Populations of Prostate Cancer Cells with Distinct Molecular, Biological, and Tumor-Propagating Properties

Advances in Brief Prostate-localized and Androgen-regulated Expression of the Membrane-bound Serine Protease TMPRSS 2 1

Molecular Characterization of Clinically Defined Aggressive Variant Prostate Cancer (avpca) in Prospectively Collected Tissues and Corresponding Patient Derived Xenografts (PDX).

The Program of Androgen-Responsive Genes in Neoplastic Prostate Epithelium.

Prostate-Localized and Androgen-Regulated Expression of the Membrane-Bound Serine Protease Tmprss2

Identification of a gene on human chromosome 8q11 that is differentially expressed during prostate-cancer progression

Prostate Short-Chain Dehydrogenase Reductase 1 (PSDR1): a New Member of the Short-Chain Steroid Dehydrogenase/reductase Family Highly Expressed in Normal and Neoplastic Prostate Epithelium.

Abstract 6282: Novel androgen related gene network in prostate cancer cell model

Gene expression alterations in human prostate cancer.

Comprehensive Analyses of Prostate Gene Expression: Convergence of Expressed Sequence Tag Databases, Transcript Profiling and Proteomics.

[Regulation of Expression of Pituitary Tumor Transforming Gene 1 (PTTG1) by Androgen in Prostate Cancer].

Transcription Variants of the Prostate-Specific PrLZ Gene and Their Interaction with 14-3-3 Proteins.

Long non‑coding RNA PART1: dual role in cancer

Insights into immune microenvironment and therapeutic targeting in androgen-associated prostate cancer subtypes

Prlz Is Expressed In Normal Prostate Development And In Human Prostate Cancer Progression

Integrated Expression Profiling And Chip-Seq Analyses Of The Growth Inhibition Response Program Of The Androgen Receptor

[Expression of Different Genes in Transitional Zone and Peripheral Zone of Human Normal Prostate].

LncRNA PART1 modulates toll-like receptor pathways to influence cell proliferation and apoptosis in prostate cancer cells

Analysis of the Androgen Receptor-Regulated Lncrna Landscape Identifies a Role for ARLNC1 in Prostate Cancer Progression